Background: There are few reports about physician and patient attitudes about antiretroviral therapy. Reports on physician perceptions of HIV-positive patients and patients' perceptions of their physicians are even scarcer. Methods: The International Association of Physicians in AIDS Care conducted surveys of HIV-treating physicians, and a separate set of HIV-positive patients. Physicians completed an online questionnaire. Patients completed a written questionnaire. Results: Physicians and patients agreed on several issues, including the priority of viral suppression when making treatment decisions and the treatment-limiting impact of side effects. However, they had diverging treatment goals in mind and differing impressions of the type and incidence of side effects. There were also sharp differences in physicians' estimates of how well patients understand HIV disease and its treatment. Conclusions: The differences revealed through these surveys underline the need to conduct a systematic study of physician and patient attitudes about antiretroviral therapy, as well as physician-patient communication.
Methods
The International Association of Physicians in AIDS Care (IAPAC) conducted 2 national surveys in 2005 to determine and compare US physician and patient opinions on antiretroviral therapy (ART) and physicianpatient relations.
Physicians were randomly selected from IAPAC's membership database and were surveyed via a 40item online questionnaire. Patients were randomly selected by AIDS service organizations in 13 cities and surveyed via a 48-item written questionnaire. Richard Day Research of Evanston, Illinois, designed the patient and physician surveys, oversaw data collection, and conducted an analysis of survey results.
Patient-respondents were not selected from the practice records of surveyed physicians, and no attempt was made to determine whether patients sought care from surveyed physicians. Thus, patient-respondents may be patients of the surveyed physicians, but given the large pools of HIV-positive patients and HIV-treating physicians in the United States, it is likely that they are not. This difference in the survey populations must be kept in mind when comparing physician and patient responses.
No attempt was made to determine the statistical significance of any responses when compared with other responses.
Results
Physician-Respondents IAPAC surveyed 152 physicians treating at least 1 patient with HIV infection weekly. Forty-seven percent of physicians treated 21 or more HIV-positive patients weekly, 26% treated 11 to 20 patients weekly, 17% treated 5 to 10 patients weekly, and only 10% treated 1 to 5 patients weekly.
Physician-respondents reported that a mean of 48% of their patients have HIV infection, and 25% said 80% to 100% of their patients are HIV-positive. Physicians averaged 16 years of experience treating HIV-positive patients, and 48% reported having 16 or more years of experience.
Patient-Respondents
IAPAC surveyed 399 patients who had been infected with HIV for a mean of 10.2 years (32% for 0 to 6 years, 42% for 7 to 14 years, 27% for 15 to 27 years). Three hundred eighteen patients (80%) were on ART at the time of the survey, 42 (10%) had suspended ART, and 39 (10%) were ART-naïve. These differences in proportions of treated and untreated patients must be kept in mind when comparing responses of patient subgroups.
Physician reports of patient treatment experience reflected patient reports, as physicians estimated that a mean of 79% of their patients were on ART.
Physicians determined that a mean of 59% of their patients had an undetectable viral load. Patients were not asked to describe their viral load.
Patients had a mean age of 44.0 years, and only 27% were under 39 years old. Seventy-two percent were male, 89% had completed at least high school, and 29% had a college degree. Only 26% of respondents had a full-time job, whereas 12% had a part-time job, and 6% described themselves as self-employed. The other patients said they were not employed and not looking for work (23%), not employed and looking for work (15%), retired (11%), a homemaker (4%), or a student (3%).
Patient Quality of Life
Although 60% of patients on treatment and 58% off treatment said HIV affected their ability to work, only 28% of ART-naïve respondents made that claim. Nearly half of the respondents on or off treatment said HIV affected their financial security, whereas 33% of ART-naïve patients cited that worry.
Whereas 58% of all patient-respondents rated their physical health as "good" or "excellent" (with little difference between on-or off-treatment groups), 45% of those on treatment and 43% of those off treatment versus 23% of those never treated said HIV "somewhat" or "very much" affected their ability to carry out activities of daily living such as eating, bathing, and dressing.
One third of all patient-respondents claimed HIV affected their emotional well-being "somewhat," and another third felt their emotional well-being was affected "very much," regardless of treatment group. Although 31% of patients believed HIV affected their ability to sustain relationships with friends and family members "somewhat," about 20% felt that impact "very much."
Treatment Objectives and Satisfaction
Most physicians and patients gave current antiretroviral (ARV) regimens high marks. A large majority of physicians claimed they are "somewhat" (65%) or "very" (14%) satisfied with current regimens. An even higher proportion of on-treatment patients (51%) reported being "very satisfied" with their current regimen, whereas 28% said they were "somewhat satisfied."
A majority of physicians either agreed (56%) or strongly agreed (16%) that "with current treatment, it is reasonable to expect that HIV patients will live a normally long life." Reflecting that response, 60% agreed and 30% strongly agreed that "with current treatments, HIV is now a manageable disease." Patients proved slightly less optimistic about their expected longevity: 28% agreed strongly and 31% agreed that they expected to live a normal lifespan.
Among physician-respondents, 45% cited side effects as their single "biggest concern" about ARV drugs, 28% cited the potential for resistance, and 7% cited cost. When multiple responses were allowed, 87% listed side effects among their concerns, 78% listed the potential for resistance, and 46% listed cost.
Among patients off treatment, the largest proportion (31%) cited side effects as their single biggest concern, whereas 15% cited taking ARV drugs as a daily reminder of their HIV infection, and 10% cited the "hassle" of taking ARV drugs every day. Among patients on treatment, 24% saw the threat of resistance as their biggest concern, whereas 17% saw therapy as a reminder of their HIV infection, and only 15% saw side effects as their top concern. An encouraging 21% in each group listed "no concerns" when asked to name their biggest problem with ART.
Although 69% of physicians listed "keeping viral load as low as possible" as an "extremely important" goal of treatment, 51% called avoiding resistance extremely important, 49% rated "keeping CD4 counts as high as possible" extremely important, and 39% listed "avoiding long-term side effects" as extremely important.
A similar proportion of patients (68% on treatment and 64% off treatment) also called controlling viral load an "extremely important" goal of ART. But even higher proportions, 70% on treatment and 74% off treatment, listed "feeling healthy" as an extremely important goal. In contrast, 55% of physicians rated keeping patients feeling healthy as an extremely important goal, though 43% called it "very important."
A plurality of physicians (44%) felt 2 objectives of ART planning are equally important: "how treatment will affect the patient's quality of life, even if it means delaying treatment or achieving suboptimal clinical outcomes," and "suppressing HIV, even though it may negatively affect a patient's quality of life." Among physicians who gave equal importance to both goals, 55% leaned toward suppressing HIV as more important and 33% leaned toward quality-oflife issues.
Importance and Frequency of Side Effects
Patient-respondents generally agreed with physicians in their relative rating of the importance of side effects. Only 23% of those on treatment and 27% of those off treatment agreed or strongly agreed that the side effects of ARV drugs are worse than HIV disease itself. In contrast, 49% of those on treatment and 44% of those off treatment disagreed or strongly disagreed with that statement. The rest neither agreed nor disagreed. Among physician-respondents, 76% disagreed or strongly disagreed that ARV drug side effects are worse than the disease itself, and another 20% neither agreed nor disagreed. Although 60% of patients on treatment and 64% of those off treatment rated "looking healthy" as an extremely important goal of ART, only 14% of physicians rated that goal extremely important. Among patients, 25% called "looking healthy" a very important goal of ART, whereas 53% of physicians gave "looking healthy" a very important rating.
One clear finding on patient attitudes about goals of ART is that most HIV-positive patients believe all the suggested goals are "extremely important," but "feeling healthy" emerged as the most important overall goal (Table 1) .
Despite patients' relatively low ranking of the importance of avoiding side effects, compared with other goals of ART, most on-treatment patients surveyed suffered from problems that may be caused by ARV drug-related side effects ( Table 2) .
Patient reports of side effect frequency make an interesting contrast with physician reports. In general, physicians reported strikingly lower frequencies of common side effects than did patient-respondents (Table 3) .
Whereas large majorities of patients reported fatigue (77%) or anxiety and depression (69%), physicians saw fatigue in only 26% of their patients and anxiety and depression in only 23%.
Starting and Switching ARV Regimens A large majority of physician-respondents follow the US Department of Health and Human Services
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents 1 (DHHS Guidelines) either "somewhat" (43%) or "very closely" (44%) when prescribing ARV regimens. Physicians report that, on average, 15% of their patients are reluctant to start ART, even after a discussion about the goals of therapy. When seeing a new patient, physicianrespondents delay initiating ART in 39%. regimens, 28% prefer a protease inhibitor (PI)-based regimen. Reflecting recent clinical trial results and DHHS Guidelines revisions, 1,2 only 2% of physicianrespondents report preferring a triple-nucleoside reverse transcriptase inhibitor (NRTI) regimen. The primary reasons physician-respondents switch ARV regimens include side effects (41% often, 7% all the time), number of pills (23% often, 3% all the time), and dosing frequency (16% often, 3% all the time). Only 4% of physicians say they switch ARV regimens because of cost. Physicians switch a mean of 5% of their patients weekly from one regimen to another "specifically because of side effects."
Among on-treatment patients, 47% say they have asked their physician to switch ARV drugs because of side effects, 19% because the dosing frequency did not fit their schedule, 15% because they found it difficult to keep track of the number of pills they were required to take, and 10% because of cost.
In a surprising response, 16 of 40 off-treatment patients (40%) said they never switched from one ARV regimen to another. The survey did not reveal why these patients suspended ART without trying a second regimen.
A majority of on-treatment patients (93%) reported knowing which ARV drugs they are taking, but only 54% knew which classes of ARV drugs they were taking. On-treatment patients reported a different NNRTI-PI balance than did physicianrespondents: 72% said they are taking a PI and 34% said they are taking an NNRTI. Only 7% reported taking an entry inhibitor. That only 56% of on-treatment patients said they are taking an NRTI confirms that patients do not understand which drug classes they are taking.
Adherence and Drug Holidays
Defining adherence as taking medications on average 93% of the time, physician-respondents believed 71% of their patients adhere to their ARV regimen. Among on-treatment patients, 84% considered themselves good adherers. But that estimation does not mirror patient reports of how often they took all their doses in the past 7 days: Only 76% of on-treatment patients had perfect adherence by that criterion, though another 10% took all their doses in 6 of the past 7 days. Among off-treatment patients, only 55% considered themselves good adherers while taking ARV drugs, a low proportion perhaps reflecting frequent side effects or other problems.
The top 3 factors physicians weigh when considering a patient's potential for adherence are recreational drug or alcohol use (80%), presence or absence of a social support network (78%), and housing situation (51%).
Physicians believed that 16% of their patients take drug holidays because of ARV drug-related side effects. Only 1% of physicians reported trying structured treatment interruptions "very often," and only 20% do so "occasionally," results reflecting generally negative findings on treatment interruptions in several clinical trials. [3] [4] [5] [6] [7] [8] [9] Patients were not surveyed about structured treatment interruptions.
Physician-Patient Relations
Physician-and patient-respondents had different perceptions of their relations with each other. An equivalent proportion of physicians said they make most decisions about their patients' treatment (47%) or that they make decisions with patients in "an equal partnership" (44%). The other 9% reported that "the patient makes most decisions, consulting with me for advice and authorization."
On the other hand, a majority of both on-treatment patients (65%) and off-treatment patients (56%) said they make treatment decisions in an equal partnership with their physicians, whereas 27% of on-treatment patients and 29% of off-treatment patients said their physicians make most treatment decisions. The remaining 8% of on-treatment patients and 12% of off-treatment patients reported they made most decisions in consultation with their physicians.
Patients and physicians also differed in how often they reported physician discussion of treatment objectives and tradeoffs. Almost all physician-respondents (87%) stated they have such discussions "very often" (45%) or "all the time" (42%). But only 24% of all patients reported that physicians had such discussions "very often" and only 26% "always." This discrepancy may reflect differing perceptions by physicians and patients, or it may indicate that few patient-respondents are treated by the physicians who were queried for this survey.
Sixty percent of physicians felt they usually have enough time for patients' questions and concerns about side effects and HIV treatment options, whereas 12% said they always have enough time to do so. Ontreatment patients gave their physicians even higher marks on this question, with 28% saying physicians usually have time to answer such questions and 57% saying physicians always do. But off-treatment patients reported somewhat less interaction with their physicians on questions related to side effects and treatment options, with 37% saying physicians often had time and 34% saying they always had time.
Physicians and patients disagreed on how often they discuss diet, physical activity, and smoking. Whereas 59% of physicians said they discuss those issues "often" and 19% "all the time," only 32% of patients reported physician counseling on these topics "very often" and 21% "always." Physician-and patient-respondents also disagreed on how often they discuss safer sex. Among physicians, 51% said they discuss safer sex "often," and 22% said they discuss safer sex "all the time." But only 15% of patients said their physicians discussed safer sex "very often" and 25% "always."
Patient Understanding of HIV Disease and Its Treatment
A high proportion of physician-respondents gave patients low ratings on their understanding of HIV disease and its treatment. A substantial 24% said "almost none" of their patients "typically understand what you tell them about HIV, treatments, and side effects," whereas 49% reported that fewer than half had such understanding and another 22% said "about half" understood what they were told about HIV. In sum, 95% of physicians believed half or fewer of their patients "typically understand" what physicians tell them about HIV disease and its treatment.
Patient-respondents had a vastly different sense of how well they understand what their physicians say about HIV: 66% reported they "almost always" understand, and 20% reported they understand more than half the time. Furthermore, 26% of patients considered themselves "extremely well informed" about HIV, and 38% self-rated as "very well informed."
In seeming contradiction with physicians' estimates of how well patients understand what physicians tell them about HIV, physicians, on average, rated 49% of their patients "very well informed" about HIV. When asked the one area in which their patients are best informed, most physicians selected adherence (51%) or side effects (31%). Nearly two thirds of physicians (65%) ranked resistance as the area about which their patients are least well informed.
Most physician-respondents (60%) thought more than half of their patients had "unrealistic expectations about HIV treatment," and another 15% thought "almost all" had unrealistic expectations.
Most patients reported that their physicians did "extremely well" (43%) or "very well" (31%) in informing them about ART. Asked to list their top 3 sources of information about ART, patients listed their physicians (83%), magazines (41%), their physician's support staff (36%), and Web sites (35%).
Discussion
Survey respondents, both physicians and patients, expressed general satisfaction with current ARV regimens. The same proportion from each group, 79%, claimed to be somewhat or very satisfied with today's ARV regimens. But opinions diverged when physicians and patients were asked whether currently available ART ensured a normal lifespan: Whereas 72% of physicians agreed or strongly agreed with that proposition, only 59% of patients did.
Two thirds of physicians and patients strongly agreed on the high priority of controlling viral load. About two thirds of patients also felt that maintaining a high CD4 count and avoiding resistance rated as high priorities, whereas 69% ranked "feeling healthy" a high priority. Patient-respondents clearly took a broad view of the goals of ART. In contrast, lower proportions of physicians gave the highest priority ranking to keeping patients feeling healthy (55%), avoiding resistance (51%), keeping CD4 counts high (49%), and avoiding long-term side effects (39%).
Physicians and patients also expressed somewhat divergent views on the impact of ARV drug-related side effects. For example, 76% of physicians disagreed or strongly disagreed with the statement that treatment side effects are worse than HIV infection itself, whereas only 49% of patients on treatment and 43% of patients off treatment disagreed or strongly disagreed with that statement.
Compared with off-treatment patients, the greater concern of on-treatment patients is resistance, suggesting that treatment failure, not toxicity, is their biggest worry. The on-treatment patients' concern about side effects, which is lower than that of the offtreatment group, suggests they have experienced fewer adverse reactions than the off-treatment group has experienced, and that difference may partly explain why these patients remain on treatment.
Patients and physicians differed on the importance of "looking healthy" as an "extremely important" treatment goal (60% of patients and 14% of physicians). Whereas 25% of patients called "looking healthy" a "very important goal," 53% of physicians ranked "looking healthy" as very important. There may be only a fine distinction between what is "extremely important" and what is "very important," but these differences suggest that patients are more concerned about how ARV drugs will affect their looks than are their physicians.
The high proportions of patients reporting sleep disturbances (73%) and dizziness (49%) suggest that many respondents were taking efavirenz (EFV), although 72% of patients reported taking a PI-based regimen and only 34% reported taking an NNRTIbased regimen. If most patient-respondents were not taking EFV, the high proportions reporting sleep disturbances and dizziness indicate that 2 problems commonly attributed to EFV often arise for other reasons. Yet on-treatment patients report that only 56% of them are taking an NRTI, suggesting some patients do not understand which ARV drugs fall in which class.
The survey revealed a great difference in proportions of patients reporting fatigue (77%) or anxiety or depression (69%) and physicians reporting those problems in patients (26% and 23%, respectively). These stark differences between physician and patient responses mean that patient-respondents were not under the care of physician-respondents, that patients feel more side effects and other problems than they report to physicians, or that physicians do not understand why patients are experiencing these symptoms and tend to dismiss them. Because precisely the same proportion of patients and physicians (32%) reported 1 objective side effect, elevated lipid levels, the difference between physician and patient responses on fatigue, anxiety, and depression suggests that most patients and physicians came from distinct practices.
Patients and physicians diverged sharply in their estimations of how well patients understand HIV disease and its treatment. As noted, many patient-respondents are likely not cared for by the physicians who were surveyed. Also, selection bias may have affected patient results on these questions, if one assumes that more knowledgeable patients may be more likely to agree to be surveyed. But even if one takes these possibilities into account, the nearly diametrically opposed ratings of how well patients understand HIV disease and its treatment suggest some failures in the physicianpatient dialogue.
This study has certain limitations. It did not attempt to create a nationally representative sample when randomly selecting either physicians or patients to survey. It did not attempt to select patients cared for by physician-respondents. And it did not attempt to balance proportions of patients who were on treatment, off treatment, and treatment-naïve. Because of these limitations, any attempt at statistical comparisons between physicians and patients or between patient groups would be unfounded.
Nevertheless, several results suggest that physicians and patients have different expectations of ART, diverging treatment goals in mind, differing impressions of the importance of side effects, and sharp differences in their estimates of how well patients understand what they are told about HIV disease and its treatment.
